



## Announcement Summary

---

**Entity name**

NEUREN PHARMACEUTICALS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Tuesday February 21, 2023

**The +securities to be quoted are:**

+Securities previously issued under an +employee incentive scheme where the restrictions on transfer have ceased or are about to cease

**Total number of +securities to be quoted**

ASX +security code	Security description	Number of +securities to be quoted	Issue date
NEU	ORDINARY FULLY PAID	300,000	21/02/2023

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

---

### 1.1 Name of entity

NEUREN PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

### 1.2 Registered number type

ABN

### Registration number

72111496130

### 1.3 ASX issuer code

NEU

### 1.4 The announcement is

New announcement

### 1.5 Date of this announcement

21/2/2023



## Part 2 - Type of Issue

---

### **2.1 The +securities to be quoted are:**

+Securities previously issued under an +employee incentive scheme where the restrictions on transfer have ceased or are about to cease

### **2.2 The +securities to be quoted are:**

Additional +securities in a class that is already quoted on ASX ("existing class")



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

---

**Additional +securities to be quoted in an existing class as a result of transfer restrictions ceasing on an existing class**

**FROM (Existing Class)**

**ASX +security code and description**

NEUAZ : ORDINARY FULLY PAID

**TO (Existing Class)**

**ASX +security code and description**

NEU : ORDINARY FULLY PAID

**Please state the number of +securities previously issued under the +employee incentive scheme where the restrictions on transfer have ceased or are about to cease**                      **And the date the restrictions on transfer have ceased or will cease**

300,000

21/2/2023

**Issue date**

21/2/2023

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes



Issue details

---

**Number of +securities to be quoted**

300,000

**Are the +securities being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid?    What is the issue price per +security?**

AUD - Australian Dollar

AUD 1.84000000

**Any other information the entity wishes to provide about the +securities to be quoted**

The consideration is repayment of the loan associated with the Loan Funded Shares.

---

Part 4 - Issued capital following quotation

---

**Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:**

**(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)**

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
NEU : ORDINARY FULLY PAID	126,265,676

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
NEUAZ : ORDINARY FULLY PAID	2,700,000
NEUAAB : OPTION EXPIRING 08-JUL-2026 EX \$3.83	750,000
NEUAAA : OPTIONS EXPIRING 03-FEB-2026 EX \$3.46	1,450,000